PARP1 and ovarian carcinoma: For instance, as demonstrated by González-Martín and colleagues, cancers with impaired homologous recombination (HR) are particularly sensitive to PARP inhibitors (PARPi) and the authors demonstrate the effectiveness of niraparib as specific therapeutic agent against HR in treating patients with ovarian cancer [6].